Mavacamten receives Breakthrough Therapy Designation in the US for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy

Mavacamten is a novel, oral, allosteric modulator of cardiac myosin. Positive data from a Phase III trial (EXPLORER) was announced by the company in May 2020, and it is currently preparing a New Drug Application for submission to the US FDA.


Biospace Inc.